Last reviewed · How we verify
NCT00246675
Frusemide Infusion for the Prevention of Deterioration in Renal Function Post Cardiac Surgery.
NA trial testing Frusemide in Renal Impairment After Cardiac Surgery. Withdrawn.
Quick facts
| Lead sponsor | Melbourne Health |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Frusemide — full drug profile →
Conditions studied
- Renal Impairment After Cardiac Surgery — all drugs for Renal Impairment After Cardiac Surgery →
Sponsor
Melbourne Health — full company profile →
Who can join
18 and older, any sex, with Renal Impairment After Cardiac Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the project is to test whether or not the commonly used medication frusemide, given after heart surgery, and aiming to increase urinary output can have an effect on kidney function.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00246675
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Frusemide
Trials testing the same drug.
- NCT05933642 — Diuretic Efficacy of Aminophylline and Furosemide Combination vs Furosemide Alone in Critically Ill Adults · Phase 2, PHASE3 · unknown
- NCT03226457 — SGLT2 Inhibition in Combination With Diuretics in Heart Failure · Phase 4 · completed
Other recruiting trials for Renal Impairment After Cardiac Surgery
Currently open trials in the same condition.
- NCT07017933 — Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes · NA · recruiting
Other Melbourne Health trials
Trials by the same sponsor.
- NCT06607367 — REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation · Phase 1, PHASE2 · not yet recruiting
- NCT05923476 — Electroconvulsive Therapy and Concomitant Lithium in Depressive Disorder: A Pilot Study · EARLY_PHASE1 · unknown
- NCT05742243 — Insulin and Abatacept in Recently-diagnosed Type 1 Diabetes · Phase 2 · completed
- NCT05577416 — A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma · EARLY_PHASE1 · completed
- NCT05005299 — Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00246675 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Melbourne Health
- Last refreshed: 27 April 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00246675.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing